InvestorWire NewsRoom


InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs
February 10, 2021

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline to its psychedelic medicine programs. These psychedelic compounds show promising potential in treating mental conditions because they are known to modulate neurotransmitters such as serotonin and dopamine, which regulate cognition, perception and mood in individuals. Called a leader in innovating psychedelic drugs in a recent article, XPhyto is focused on helping individuals who suffer from mental health disorders, including the 11% of Americans that the U.S. Center for Disease Control (“CDC”) reports have contemplated suicide since the outbreak of the COVID-19 pandemic. The number is similar in the UK. A growing number of studies indicate that psychedelic drugs can be effective in treating chronic and serious forms of depression that typically do not respond to existing treatments. Psychedelics are also being studied for the treatment of  drug and alcohol addictions as well as post-traumatic stress disorder (“PTSD”). Raimar Löbenberg, a director at XPhyto Therapeutics, is one of a limited few medical scientists in North America who has gained the necessary government-level clearance to experiment in a university laboratory setting with highly regulated Schedule 1 drugs; psychedelics currently fall into this category. Regarding XPhyto Labs, the addition of mescaline to its medicine programs comes as the substance has shown potential as a treatment for addiction and depression. A Schedule I drug, mescaline is used with traditional Native American religious rituals and ceremonies and its becoming increasingly popular as a supplement to meditation and psychedelic therapy. “Our initial focus is to develop standardised drug formulations with precise, predictable and efficient delivery of their active pharmaceutical ingredients for clinical study and therapeutic use,” said XPhyto director Raimar Löbenberg in the article. “We see a lot of potential therapeutic value in psychedelic compounds for their ability to positively influence neural networks through growth and reorganisation.”

To view the full article and press release, visit and

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).